Drug Pricing, Overreach Dominate IP Disclaimer Feedback
By Dani Kass · July 10, 2024, 10:18 PM EDT
The U.S. Patent and Trademark Office has received heated feedback regarding its proposal to make follow-on patents easier to invalidate, with drug pricing advocates applauding it, top technology and pharma companies...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login